MISTLETOE THERAPY • INTEGRATIVE CANCER CARE
Mistletoe Therapy for Cancer at Sunridge Medical
Coordinate Mistletoe Therapy With Your Oncology Treatment
Mistletoe preparations, routes and evidence differ by setting. A physician can review the cancer type, active treatment, immune status, product and goals before building a monitored plan.
- The exact preparation, route and schedule are reviewed
- Reactions and oncology timing are monitored
- Call now for an immediate response from our Patient Care Team
Speak With Our Patient Care Team
Share your diagnosis, current treatment and the mistletoe product or route you are considering.
- The exact preparation, route and schedule are reviewed
- Reactions and oncology timing are monitored
- Questions before scheduling are always welcome
Sunridge has years of experience incorporating European mistletoe preparations—including Helixor and Iscador—into individualized cancer-care plans. Selected patients may receive mistletoe by supervised intravenous infusion or subcutaneous injection, with formulation, dose and schedule chosen by the medical team.
✓ Onsite infusion rooms ✓ Nursing supervision ✓ Individualized protocols
Years of clinical use
Experienced integrative cancer-care team
European preparations
Helixor, Iscador and host-tree options
In-house treatment
Comfortable IV rooms and nursing support
Personalized planning
Selected around the whole treatment plan
EUROPEAN MISTLETOE • VISCUM ALBUM
What is mistletoe therapy?
Mistletoe therapy uses preparations made from Viscum album, the European mistletoe plant. Injectable extracts have a long history of use in European integrative oncology and remain among the most extensively studied complementary therapies used alongside cancer care.
Mistletoe is not one uniform product. Preparations differ according to the host tree, harvest, manufacturing method and concentration of biologically active compounds such as mistletoe lectins and viscotoxins. That is why selection and dosing are clinical decisions—not a one-size-fits-all protocol.
Viscum album
Different host trees and preparations are selected for different clinical contexts.
TREATMENT AT SUNRIDGE
Mistletoe is delivered as part of a complete cancer-care plan
Sunridge is an active treatment facility with a full nursing team and dedicated infusion rooms. Patients come to the Scottsdale clinic to receive therapies, sometimes on a concentrated schedule when they are visiting Arizona for a limited period.
Mistletoe may be used by itself as a supportive treatment component or coordinated with other physician-directed strategies. The medical team reviews the diagnosis, current and prior cancer therapy, medications, laboratory findings, immune history and treatment goals before recommending a preparation or route.
FORMULATIONS & ROUTES
Iscador, Helixor and individualized mistletoe protocols
The brand name alone does not determine the protocol. Host tree, concentration, route, dose escalation, timing and patient response all matter.
Iscador
A widely used European mistletoe preparation available in host-tree-specific formulations. The appropriate product and dosing series are selected clinically.
Helixor
A German mistletoe preparation used in subcutaneous and intravenous clinical settings. Helixor M was studied in a U.S. phase I IV trial.
Route and schedule
Subcutaneous injection is the most studied route. Sunridge may also use supervised IV mistletoe for selected patients when clinically appropriate.
WHY PATIENTS CONSIDER MISTLETOE
Supportive goals that matter during cancer treatment
The strongest recurring research themes involve quality of life and treatment tolerance. Individual results vary, and the evidence is not equally strong for every cancer type or outcome.
Quality of life
Systematic reviews and clinical studies have reported improvements in quality-of-life measures in some cancer populations, although study quality varies.
Treatment tolerance
Mistletoe has often been studied as an add-on during conventional treatment, with interest in fatigue, nausea, pain and treatment-related symptoms.
Immune signaling
Laboratory research describes effects on natural killer cells, cytokines and other immune pathways. Clinical meaning depends on the patient and treatment context.
Supportive integration
At Sunridge, mistletoe is considered as one component of a broader plan—not a substitute for necessary oncology evaluation or treatment.
INTRAVENOUS MISTLETOE
Supervised IV mistletoe in a dedicated treatment setting
A 2023 Johns Hopkins phase I study evaluated IV Helixor M in 21 people with heavily pretreated advanced solid tumors. The study was designed primarily to evaluate safety and dosing. It reported a manageable safety profile, five patients with stable disease, early quality-of-life improvement and no objective tumor responses.
Sunridge uses clinical screening, preparation-specific dosing and nursing observation when IV mistletoe is selected. Frequency may be adjusted according to the treatment plan, response and the patient’s time in Scottsdale.
WHAT TO EXPECT
How a mistletoe plan is built
01
Case review
Cancer type, stage, treatment history, medications, laboratory findings and goals are reviewed.
02
Preparation selection
The physician selects the mistletoe preparation, host-tree formulation, route and starting approach.
03
Treatment and observation
Subcutaneous teaching or supervised IV treatment is provided with nursing support.
04
Dose adjustment
Tolerance, local or systemic reactions, symptoms and the broader cancer plan guide changes.
RESEARCH IN CONTEXT
A positive signal—without oversimplifying the evidence
Mistletoe is one of the most studied complementary therapies in oncology. A 2020 meta-analysis of 30 controlled datasets reported a medium-sized improvement in global quality of life. A 2023 breast-cancer review also reported quality-of-life improvement in randomized studies, while noting variable risk of bias.
The National Cancer Institute describes mistletoe as widely used in Europe and summarizes research across breast, colorectal, pancreatic, lung and other cancers. At the same time, NCI notes that study limitations prevent broad conclusions about survival or tumor control. Sunridge presents mistletoe as a physician-directed integrative option whose role must be individualized.
SAFETY & COORDINATION
Mistletoe should be medically supervised
Expected reactions can include redness, warmth, swelling or itching at an injection site, along with fatigue, fever, chills, headache or nausea. Serious allergic reactions are uncommon but have been reported. Route, formulation and dose influence the safety profile.
Patients should tell the Sunridge team about autoimmune disease, immune-suppressing medication, checkpoint-inhibitor therapy, transplant history, allergies and all current cancer treatments. Mistletoe is not FDA-approved as a cancer treatment in the United States and should not replace standard oncology care without a fully informed medical decision.
COMMON QUESTIONS
Mistletoe therapy questions patients ask us
RESEARCH & HELPFUL LINKS
Continue exploring mistletoe and integrative cancer care
These materials are educational. External publications do not represent an endorsement of every statement or protocol they contain.
National Cancer Institute
Patient overview of mistletoe extracts, routes, research and safety.
2023 IV Helixor M Trial
Open-access phase I study of intravenous mistletoe in advanced solid tumors.
Quality-of-Life Meta-analysis
Systematic review and meta-analysis of controlled mistletoe studies.
Alternative Cancer Treatments
Return to the Sunridge treatment pillar and explore other physician-directed options.
Sunridge Mistletoe Patient Guide
Download the original Sunridge Medical guide to mistletoe preparations, treatment routes, research and safety.
Mistletoe studies and evidence reviews
The links below include the studies and evidence reviews previously listed on this page. Select any title to open the original NCI or PubMed record in a new tab.
- National Cancer Institute. Mistletoe Extracts (PDQ®) – Health Professional Version. Evidence review of preparations, mechanisms, routes, clinical studies, safety and regulatory status.
- Paller CJ, et al. Phase I Trial of Intravenous Mistletoe Extract in Advanced Cancer. Cancer Research Communications. 2023. PMID: 36860652.
- Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. 2020. PMID: 32690087.
- Freuding M, et al. Mistletoe in oncological treatment: a systematic review. Part 1: survival and safety. 2019. PMID: 30673873.
- Tröger W, et al. Viscum album extract therapy in locally advanced or metastatic pancreatic cancer: randomized trial on overall survival. 2013. PMID: 23890767.
- Tröger W, et al. Quality of life in advanced pancreatic cancer during mistletoe treatment: randomized controlled trial. 2014. PMID: 25142075.
- Wode K, et al. Mistletoe Extract in Patients With Advanced Pancreatic Cancer: placebo-controlled randomized clinical trial. 2024. PMID: 38915151.
- Vella R, et al. Unconventional Treatments for Pancreatic Cancer: A Systematic Review. 2025. PMID: 40361364.
- Bar-Sela G, et al. Mistletoe as complementary treatment in advanced non-small-cell lung cancer: randomized phase II study. 2013. PMID: 23218588.
- Tröger W, et al. Five-year follow-up in early-stage breast cancer after additional Viscum album treatment. PMID: 23150723.
- Duncan LJ, et al. The Mistletoe and Breast Cancer (MAB) Study: UK pilot randomized placebo-controlled feasibility study. 2025. PMID: 41097697.
- Bar-Sela G, Haim N. Abnoba-viscum in metastatic colorectal carcinoma resistant to chemotherapy. 2004. PMID: 15456952.
- Augustin M, et al. Long-term adjuvant fermented European mistletoe extract in high-risk malignant melanoma. 2005. PMID: 15727163.
- Piao BK, et al. Impact of complementary mistletoe extract on quality of life in breast, ovarian and lung cancer. 2004. PMID: 15015612.
- Rose A, et al. Mistletoe Plant Extract in Nonmuscle Invasive Bladder Cancer: Phase Ib/IIa dose-escalation study. 2015. PMID: 25910967.
- Weissenstein U, et al. Interaction of standardized mistletoe extract with chemotherapeutic drugs in vitro. 2014. PMID: 24397864.
START WITH A CONVERSATION
Could mistletoe fit your cancer treatment plan?
Tell our Patient Care Team about your diagnosis, current treatments and goals. We can explain the review process and help you prepare records for a physician consultation.
Research organized by cancer type
Browse 6 source-linked studies with the full title, publication year, research focus and a concise finding. Select any linked cancer type to move directly to its corresponding Sunridge page.
Inhibition of osteosarcoma by European Mistletoe derived val-miR218.
This study aimed to investigate whether mistletoe miRNAs, specifically val-miR218, exert anti-cancer activity against osteosarcoma.
The Mistletoe and Breast Cancer (MAB) Study: A UK Mixed-Phase, Pilot, Placebo-Controlled, Double-Blind, Randomised Controlled Trial.
To test the feasibility of a mixed-phase, pilot, placebo-controlled, double-blind trial of mistletoe therapy (MT) with an embedded qualitative study in the UK National Health Service (NHS) setting.
Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
We found that ML treatment inhibits growth of SCLC cell lines in culture and induces apoptosis.
Mistletoe Extracts Inhibit Progressive Growth of Prostate Cancer Cells.
All mistletoe extracts significantly inhibited cell growth in a dose-dependent manner and cell proliferation and clonogenicity were suppressed.
Inhibition of osteosarcoma by European Mistletoe derived val-miR218.
This study aimed to investigate whether mistletoe miRNAs, specifically val-miR218, exert anti-cancer activity against osteosarcoma.
MISTOSUS: a phase II trial of Viscum album extract adjuvant therapy for relapsed resectable osteosarcoma.
Viscum album extract has a long history of use in Europe and a track record of safety in children which allowed for the opening of a Phase II trial in the US to test the efficacy of Viscum album extract to improve PREFS in children and AYAs with relapsed osteosarcoma.
No studies match those filters. Clear a filter or try a broader term.